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Abstract
Background:  We studied the effects of access to point-of-care medical evidence in a
computerised physician order entry system (CPOE) on management and clinical outcome of
children with bronchiolitis.
Methods: This was a before-after study that took place in a Canadian tertiary care paediatric
teaching hospital. The intervention was a clinical evidence module (CEM) for bronchiolitis
management, adapted from Clinical Evidence (BMJ Publishing Group) and integrated into the
hospital CPOE. CPOE users were medical trainees under the supervision of staff physicians
working in the infant ward. Use of antibiotics, bronchodilators and corticosteroids; disease
severity; length of hospital admission; and trainee use and perception of the CEM were measured
before and after CEM introduction.
Results: 334 paediatric inpatients age 2 weeks to 2 years, with a clinical diagnosis of bronchiolitis;
147 children the year preceding and 187 children the year following introduction of a Clinical
Evidence Module (CEM). The percentage of patients receiving antibiotics fell from 35% to 22%
(relative decrease 37%) following the introduction of the CEM (p = 0.016). Bronchodilator use was
high but following the CEM patients no longer received more than one variety. Steroid usage and
length of hospitalisation were low and unaffected. Trainees found the CEM to be educational.
Conclusion:  Readily accessible clinical evidence at the point of care was associated with a
significant decrease in antibiotic use and an end to multiple bronchodilator use. The majority of
physician trainees found the CEM to be a useful educational tool.
Background
A computerised clinical decision support system (CDSS)
may improve the efficiency and efficacy of patient care, in
part by facilitating incorporation of clinical evidence into
therapeutic decision-making. As with all health care inno-
vations, CDSSs require rigorous evaluation before their
widespread use in patient care[1]. A systematic review of
68 controlled trials found improvements in health care
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practitioner performance with 66% of the innovations,
principally in drug dosing and preventive care for treat-
ment of hypertension, diabetes and acquired immunode-
ficiency syndrome[2]. Another, more recent systematic
review found that successful CDSSs are computerised,
provide decision support as part of clinician workflow,
provide recommendations rather than just assessments,
and provide decision support at the time and location of
decision making[3].
Bronchiolitis was chosen as the context for evaluation of
a computer-based CDSS providing medical evidence at
the point of care. This virus-induced acute inflammation
of the lower respiratory tract is the most common reason
for hospitalisation of infants. Over 100,000 children
under 1 year of age are hospitalised annually in North
America, with an estimated annual health care cost of
more than $300,000,000[4]. Bronchiolitis treatment is
largely supportive, although therapies (bronchodilators,
systemic steroids, and antibiotics) may benefit some
patients. Evidence-based clinical practice guidelines have
modified care and improved clinical outcome[5-7].
Despite these guidelines, published studies of bronchioli-
tis treatment often contradict each other, and may be con-
trary to local management strategies. For instance, supra-
infection with bacteria in uncomplicated cases of bronchi-
olitis is uncommon and the recommendation has been
not to routinely use antimicrobials. However, antibiotics
are commonly given to many hospitalised infants[8,9].
Needless antimicrobial therapy has significant care impli-
cations, because antibiotics confer potential risks of infec-
tion with resistant bacteria, as well as adverse drug
reactions. Successful implementation of a clinical evi-
dence CDSS depends upon high quality credible informa-
tion, ready access within existing tasks, upkeep of the
information as research evolves and assessment of physi-
cian actions and patient outcomes. These elements were
incorporated into this study, wherein point-of-care access
to up-to-date clinical evidence regarding bronchiolitis
management in hospitalised children was provided
through a computerized physician order entry system
(CPOE) to medical students and residents.
Methods
Study design, setting
A quasi experimental before-after study conducted at the
Children's Hospital of Eastern Ontario (CHEO), a tertiary
care paediatric hospital in Ottawa, Canada. The CHEO
Research Ethics Committee approved the study.
Study population
Bronchiolitis patients on CHEO's infant ward were iden-
tified by discharge diagnosis ICD-9-CM codes (ICD-9
codes:466.11, 466.19 and 480.1)[10] during peak bron-
chiolitis periods: pre-intervention November 01, 2000 –
March 31, 2001; and intervention November 01, 2001 –
March 31, 2002. Participants were included if they were
age 2 weeks to 2 years. Patients with a pre-existing diagno-
sis of asthma or patients with wheezing and/or cough who
had previously been treated with bronchodilators or ster-
oids were excluded.
Residents and medical students from the University of
Ottawa entered all orders, under the supervision of the
attending staff doctor.
Intervention
A clinical evidence module (CEM) was integrated into the
Medical Logic Module of CHEO's CPOE system (Sunrise
Clinical Manager™, Eclipsys Corporation, Boca Raton,
FL).
The CEM was based on the information in "Clinical Evi-
dence", a monthly, updated review of evidence on the
effects of common clinical interventions, used with per-
mission from the BMJ Publishing Group[11]. Electronic
searches of Medline were also used to monitor the medi-
cal literature during the intervention period, but no
changes were made to the CEM.
The CEM was available when trainees and physicians on
CHEO's infant ward selected the bronchiolitis order entry
set. The top quarter of the screen was entitled "Evidence
Based Care", with options to view evidence regarding:
antibiotics; bronchodilators; corticosteroids; ribavirin;
immunoglobulins; and nursing interventions (Figure 1).
The user could access a "bottom line" summary of the evi-
dence as well as more complete syntheses for individual
topics, and integrate the evidence as deemed clinically
suitable. Physicians and trainees were informed by e-
mails and reminded at monthly staff meetings that the
CEM was available. They were not informed that manage-
ment of bronchiolitis patients would be monitored, in
order to minimise the potential impact of that measure-
ment on their practice.
Outcome measures
The primary outcome measures were the frequency of
ordering of antibiotics, bronchodilators and corticoster-
oids. Ribavirin, immunoglobulin and nursing interven-
tions were not included as outcome measures a priori, as
existing hospital guidelines governed the use of these
interventions.
The secondary outcome measure was the length of stay in
hospital (LOS).
In order to compare the severity of patients' illness, as well
as costs of hospitalisation, the resource intensity weight-BMC Pediatrics 2007, 7:4 http://www.biomedcentral.com/1471-2431/7/4
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ing (RIW) of each hospitalisation was calculated[12]. The
RIW is a standard administrative factor generated based
on discharge diagnoses and hospitalisation chart review.
Antibiotic use for patients on the infant study ward who
did not have a diagnosis of bronchiolitis and antibiotic
use for all patients in hospital during the study period
were tabulated.
Outcome measures were extracted electronically from
hospital pharmacy and discharge records.
Statistical analysis
Age and illness severity were compared between study
groups using Wilcoxon rank sum tests, and gender was
compared using Fisher's exact test. Due to a significant dif-
ference in age between pre- and post-intervention groups,
all subsequent analyses were adjusted for child's age
within the regression model. Differences in the use of
antibiotics, bronchodilators and steroids were assessed
using Chi-square or Fisher's exact tests. Number of doses
of those three principal medications were analysed using
Poisson regression models. Cox regression models were fit
to assess a difference in both length of stay in the hospital
and length of stay on the floor. All reported p-values are
two-sided and were declared statistically significant when
they reached a 0.05 probability level.
Post-intervention feedback
A 12-question survey of students and residents addressed
utilisation, usefulness, potential improvements and gen-
eral applicability of the CEM (see Additional 1).
Screen Shot of CEM and Bronchiolitis Order Entry Set Figure 1
Screen Shot of CEM and Bronchiolitis Order Entry Set. (Used with permission of Eclipsys Corporation, Boca Raton, 
FL).BMC Pediatrics 2007, 7:4 http://www.biomedcentral.com/1471-2431/7/4
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Results
A total of 334 children with a median age of 0.41 years
(range: 0.02, 1.99) participated in this study; 147 children
the year preceding and 187 children the year following the
introduction of the CEM. There were no differences
between the study groups with respect to gender or illness
severity, as measured by the RIW. However, the group fol-
lowing introduction of the CEM were younger (p = 0.021)
(Table 1).
The proportion of patients receiving antibiotics fell from
35% to 22% (relative decrease of 37%) following the
introduction of the CEM (p = 0.019) (Table 2). At the
same time, there was no significant difference in antibi-
otic use for other patients on the infant ward (originally
estimated to 49.4% followed by a relative increase of
4.5%, p = 0.541). Similarly, no significant change was
detected in the total population of hospitalized patients
receiving antibiotics (originally 45.9% with a relative
decrease of 7.0%, p = 0.265).
Bronchodilator use was universally high (94%) prior to
and following the introduction of the CEM, but physi-
cians had less variation in bronchodilator medications
prescribed. Salbutamol was preferred over epinephrine
before the introduction of the CEM, while preference was
reversed when clinical evidence was provided (Table 2).
Corticosteroid use was uniformly low prior to (14%) and
following (13%) the intervention (Table 2).
Median length of stay (LOS), from the time of registration
in the emergency department to discharge from the hospi-
tal, increased from 2.8 to 2.9 days following introduction
of the CEM (p = 0.125). Median LOS on the floor was
unchanged prior to and following introduction of the
CEM (2.8 days).
Fifty surveys were returned (90% response rate) from
medical trainees; 19 (38%) residents and 31 (62%) med-
ical students. Although 94% of respondents had admitted
a patient with bronchiolitis, 55% stated that they were
unaware of the CEM availability. Medical students (19%)
were less likely and paediatric residents (77%) more likely
to have reviewed the CEM. Of respondents who had read
the CEM, all medical students reported that the review
was clinically helpful while 29% of the senior pediatric
residents reported that the information was not of assist-
ance. All respondents agreed that the CEM had been edu-
cational and that point of care evidence would have merit
if expanded to other clinical conditions.
Discussion
In an increasingly complex medical environment, deci-
sion support systems are promising tools for clinicians,
overloaded with information. While a CDSS enables the
delivery of evidence-based practice at the point of care,
considerable challenges exist for CDSS to support the
management of complex and multiple medical condi-
tions[13]. In this study Bronchiolitis provided a context to
evaluate a computer-based CDSS wherein clinical evi-
dence was made readily available on a commercial CPOE
system. There is evidence that implementing bronchiolitis
clinical practice guidelines at the point of care decreases
unwarranted treatment variation[7,8,14]. Also, selected
CDSSs have been able to improve physician performance
and substantially reduce medication error rates, though
the actual impact on patient outcomes is unknown[3,15].
Evaluating the effectiveness of specific elements of a CDSS
and its delivery via a commercial CPOE system on a busy
inpatient unit revealed that the clinical management of
infants hospitalised with bronchiolitis was improved.
There was a decrease in the proportion of patients receiv-
ing antibiotics and while a large proportion of patients
continued to receive bronchodilators, fewer patients
received multiple bronchodilators. The current Clinical
Evidence[16] does not support the routine use of bron-
chodilators for hospitalised infants, however, the CEM
used in this study quoted an older version of Clinical Evi-
dence that recommended a trial dose of a bronchodilator,
and to discontinue this therapy if there is no
response[11]. Perhaps, this accounted for the decrease in
the variation of the bronchodilators prescribed. Steroid
use was low, and LOS in the ward was consistently < 3
days for the medians of the populations. They remained
unchanged.
The limitations of this study highlight difficulties in the
evaluation of interventions to improve complex systems
of health care. For instance, the observational study
design and lack of blinding are potential sources of bias.
Table 1: Characteristics of Study Participants
Characteristics Pre-CEM introduction 2000 – 2001 Post-CEM introduction 2001 – 2002 p-value
Age in years, median (range) 0.50 (0.03, 1.97) 0.36 (0.02, 1.99) 0.021
RIW, median (range) 0.63 (0.57, 3.94) 0.63 (0.63, 7.91) 0.186
Male, n (%) 83 (56.5) 113 (60.4) 0.502BMC Pediatrics 2007, 7:4 http://www.biomedcentral.com/1471-2431/7/4
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While the simple study design and straightforward out-
come measures yielded clear results in terms of physi-
cians' orders for antibiotics and bronchodilators, the
study demonstrates associations between the use of the
intervention, the observed outcomes and the process
measures and does not prove a direct cause-and-effect
relationship. Though we were not aware of any, other
changes in bronchiolitis treatment patterns or antibiotic
usage during the study period, such as other written or
electronic guidelines, lectures, or handouts, may have
influenced orders. However, for antibiotic usage we were
able to demonstrate a decrease in usage specific to bron-
chiolitis while antibiotic use for other conditions and in
other hospital units stayed the same or increased during
the study. While many of the trainees entering orders were
not aware of the intervention, this was primarily among
medical students whose admitting orders are reviewed by
senior pediatric residents, the majority of whom had
reviewed the CEM. A difference in infants' age could
potentially influence antibiotic use. However, fewer anti-
biotics were administered to the younger group, although
physicians might be expected to be more likely to order
antibiotics for younger infants[17]. A clinical order set for
bronchiolitis was developed and incorporated into the
CPOE system two years prior to the initiation of the study,
so ready access to electronic order-sets was not a co-inter-
vention. All treatment measurements were straightfor-
ward and exact, from computerised medical records, so
the data were valid and reproducible.
Antibiotic over-use may have been addressed by other ini-
tiatives within the hospital or medical school. However,
such a co-intervention would be expected to have a uni-
versal effect, and antibiotic use decreased only amongst
the bronchiolitis patients. Although antibiotic use fell by
37%, a quarter of the patients continued to receive them.
Table 2: Antibiotic, Bronchodilator and Steroid use Prior to and Following CEM Introduction
Pre-CEM 2000 – 2001 n = 142 Post-CEM 2001 – 2002 n = 174 Difference (95% CI) p-value
Antibiotic Prescription Patterns for Bronchiolitis Patients
Antibiotics, n (%) 49 (34.5) 38 (21.8) 12.7 (2.7, 22.5) 0.020
# antibiotics received:
0, n (%) 93 (65.5) 136 (78.2)
1, n (%) 28 (19.7) 22 (12.6)
2, n (%) 16 (11.3) 12 (6.9)
3, n (%) 4 (2.8) 3 (1.7)
4, n (%) 1 (0.7) 1 (0.6)
Median (range) 0 (0, 4) 0 (0, 4) 0 (0,0) 0.019
Bronchodilator Prescription Patterns for Bronchiolitis Patients
Bronchodilators, n(%) 134 (94.4) 163 (93.7) 0.7 (-5.1, 6.1) 0.873
Salbutamol received, n (%) 102 (71.8) 77 (44.3) 27.6 (16.9, 37.4) <0.001
Epinephrine received, n (%) 72 (50.7) 120 (69.0) -18.3 (-28.6, -7.4) 0.005
Number of different bronchodilators received
0 received, n (%) 8 (5.6) 11 (6.3)
1 received, n (%) 57 (40.1) 64 (36.8)
2 received, n (%) 37 (26,1) 37 (21.3)
3 received, n (%) 18 (12.7) 34 (19.5)
≥ 4 received, n (%) 22 (15.5) 28 (16.1)
Median (range) 2 (0, 8) 2 (0, 9) 0 (0, 0) 0.637
Steroid Prescription Patterns for Bronchiolitis Patients
Inhaled Steroids
0, n (%) 132 (93.0) 167 (96.0)
1, n (%) 10 (7.0) 6 (3.4)
2, n (%) 0 (0.0) 1 (0.6)
Median (range) 0 (0, 1) 0 (0, 2) 0 (0, 0) 0.510
Systemic Steroids
0, n (%) 129 (90.8) 157 (90.2)
1, n (%) 13 (9.2) 17 (9.8)
Median (range) 0 (0, 1) 0 (0,1) 0 (0, 0) 0.629
Total Inhaled and Systemic steroids
0, n (%) 122 (85.9) 152 (87.4)
1, n (%) 17 (12.0) 19 (10.9)
2, n (%) 3 (2.1) 3 (1.7)
Median (range) 0 (0, 2) 0 (0,2) 0 (0, 0) 0.983BMC Pediatrics 2007, 7:4 http://www.biomedcentral.com/1471-2431/7/4
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This compares favourably with reports of antibiotic
administration to over half of bronchiolitis
patients[9,18], but it would be desirable to decrease usage
to as low a level as possible; antibiotic orders for only 9%
of bronchiolitis patients has safely been achieved[7].
Finally, while this intervention had three of the four char-
acteristics associated with success for CDSSs[3], it did not
require acknowledgement or action as part of the work
flow. This appears to be important, because about half of
the medical trainees who encountered the CEM did not
notice it.
Implementation and routine updating of computerized
CDSS would require scarce resources allocated for patient
care, so innovations must be evaluated to ensure that they
are both economical and effective, to improve outcomes
for patients and education of medical trainees. The impli-
cation of this study for clinicians and policymakers is that
ready access to valid, relevant information empowers
trainees to make evidence-based treatment choices, and
may increase future use of evidence in clinical decision-
making[19]. In this teaching hospital, the CEM served the
dual role of improving clinical practice, and of imparting
important information to medical trainees at an oppor-
tune moment. The majority of trainees, particularly those
more junior in their training, found the provision of evi-
dence at the point of care beneficial.
Conclusion
In summary, provision of clinical evidence from a reputa-
ble source at the point of care influenced bronchiolitis
treatment choices by medical trainees, at least in the areas
of antibiotic and bronchodilator use. This model for pro-
viding information may be a helpful educational tool, as
well as a means of improving patient health care manage-
ment for other diseases. In the future we plan to study
optimization of the operation, appearance and position-
ing in the computerised order entry process, and co-inter-
ventions to maximise utilisation.
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